QualityStocks.net News – Insmed Inc. (INSM) Shares Climb 15% on Word of Positive Bioequivalence Testing

QualityStocks.net News – Insmed Inc. (INSM) Shares Climb 15% on Word of Positive Bioequivalence Testing

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight Insmed Inc. (NASDAQ: INSM). The company is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.

In the company’s recent news,

Shares of Insmed Inc. (INSM) hiked 15% to a close of 46 cents yesterday; spurred by word the biopharmaceutical company has demonstrated the bioequivalence of INS-19, the company’s recombinant human granulocyte colony stimulating factor (G-CSF). The company compared G-CSF to FDA-approved Neupogen, used to treat neutropenia, a disorder characterized by an abnormally low number of white blood cells.

“These results are very exciting, as they represent Insmed’s ability to replicate a protein product, to bring that product rapidly through the clinic and to demonstrate clear bioequivalence to the innovator drug,” Dr. Geoffrey Allan, president and CEO of Insmed stated in the press release. “To our knowledge, we are the first U.S. company to report human bioequivalence data for a follow-on biologic product, validating the idea that follow-on biologics can be a scientific reality in the U.S. and that Insmed is well positioned to be a leader in the field.”

The human bioequivalence studies followed the FDA’s strict standards to demonstrate the equivalence between Insmed’s INS-19 and Neupogen. Results show the primary pharmacodynamic marker for G-CSF products had the same response for INS-19 and Neupogen products.

“Demonstration of bioequivalence is typically the sole clinical requirement to support FDA approval of generic drugs today. Thus, based on these data, Insmed intends to request a meeting with the FDA to discuss potentially initiating a phase III clinical trial program for INS-19,” Allan stated.

The positive results are integral to Insmed’s product pipeline. Neupogen recorded 2007 sales of approximately $1 billion, marking a huge window of opportunity for Insmed’s INS-19 as it steps toward commercialization.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.